Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia

We report a case of severe, refractory gastrointestinal (GI) bleeding in a patient with hereditary hemorrhagic telangiectasia (HHT) whose massive transfusion dependence was lifted shortly after treatment with bevacizumab, an anti-vascular endothelial growth factor. The patient’s bleeding had been re...

Descripción completa

Detalles Bibliográficos
Autores principales: Ou, George, Galorport, Cherry, Enns, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5183923/
https://www.ncbi.nlm.nih.gov/pubmed/28070235
http://dx.doi.org/10.4240/wjgs.v8.i12.792

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5183923/
https://www.ncbi.nlm.nih.gov/pubmed/28070235
http://dx.doi.org/10.4240/wjgs.v8.i12.792

Ejemplares similares